Financial Performance - Moderna's revenue surged from approximately $60 million in 2020 to over $19 billion in 2023 due to its mRNA technology and COVID-19 vaccine development [1][3] - However, COVID-related revenue has declined to $1.9 billion, and the company's cash reserves have decreased from over $10 billion to roughly $5.8 billion [4] Product Development - Moderna is currently developing an influenza vaccine that is under review by the FDA, with potential approval before the next flu season [5] - The company is collaborating with Merck on a melanoma therapy, which shows promising trial results but is still in the testing phase [6] Future Outlook - There is caution regarding Moderna's future as it has not yet launched a major new product following its COVID success, leading to elevated spending and stagnant revenue growth [7]